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in theu rata during or after GM •• dmin;atzation. 
In the experiment 2 model. GM~ wu injected intravenously. 
No complications were seen after daily injections for 7 days 
after transplantation using a dose of 3 mg/kg GM3• The mech-
anisms of action of GM3 on the prolongation of allograft 
survival were usessed by immunohistochemistry. These studies 
suggested that the inhibitory activity of GM3 resulted from 
significant suppression of macrophages and cytotoxic T lym-
phocytes. thereby supporting the results of Hoon et al. and 
others showing that GMJ inhibits both IL-2 and IL-2 receptors 
(2. 7. 8). GM~ might have some unique characteristics u an 
immunosuppressive agent in organ transplantation. Bremer et 
a1. studied the incorporation of exogenously added GM3 into 
Swiss 3T3 cells in vitro (15). The data revealed that GM3 wu 
absorbed by the cell surface and incorporated into the cell 
membrane after 48 hr. Thus. when GM3 is injected directly 
into the transplanted organ. it may be absorbed into the tissue, 
which reduces the susceptibility to immune attack. It may be 
possible to reduce the incidence of systemic infection with local 
administration of GM3 and also to suppress the immune re-
sponse during preservation using a solution containing GM3. 
In addition. GM3 is a molecule present in vivo as a natural 
substance. Therefore. toxicity would be much less than that of 
conventional immunosuppressants. Furthermore. Sugimoto 
and Ogawa demonstrated a method for synthesizing GM~ chem-
ically (]6). Thus GM, could be used in conjunction with con-
ventional immunosuppressants. thereby reducing the required 
doses and preventing severe complications after transplanta-
tion. 
In conclusion. the present study suggests that GM, has a 
significant immunosuppressive effect on transplanted heans 
and that it may be a useful immunosuppressive agent for organ 
transplantation. 
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DENDRITIC CELL REPLACEMENT IN LONG-SURVIVING LIVER AND CARDIAC XENOGRAITSI 
We described recently how immunosuppression with FK 506 
alone markedly prolonged the survival in rats of nonarterialized 
I This work was IUpported by Reaearch Grants from the Veterans 
Adminiltration and Project Grant No. DK 29961 from the National 
lnatitutea of Health. Betheada. MD. 
orthotopic hamster liver xenografts. but not heart xenografts 
revascularized in the abdominal cavity (1 ). We report here that 
addition of splenectomy to FK 506 prolonged survival of heart 
grafts from a mean of 3 days in untreated controls (n-6) to 
> 100 days (7 of 7). permitting us to determine with both organs 
if the donor dendritic cella were replaced. Male LVG hamatera 
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1120-150 g) and male Lewis rata (240-280 g) were used as 
donors and recipients. respectively. The transplant procedures 
were performed under methoxyflurane anesthesia in the same 
way as described before (1 ). except that the heart recipients 
underwent contemporaneous splenectOmy. 
Liver recipients were ~ven 1 mg/kg/day intramuscular FK 
506 (Fujisawa Pharmaceutical Co .. Osaka. Japan) for 30 days 
and 0.5 mg/kg every other day for another 70 days. terminating 
treatment on day 100. The splenectomized heart recipients 
were treated with 2 mg/kg/day FK 506 for 30 days. and there· 
after were treated the same as the liver recipients up to 100 
days. 
Survival of the liver recipienta waa prolonged with FK 506 
from 7.0±O.5 days in untreated controls In=8) to 66.7±57.9 
days (n=1O). with 3 of the recipients survivinlt more than 100 
days. The main cause of delayed death under treatment was 
obstruction of the bile duct. usually with minor histopatholo~c 
findings of cellular rejection. After FK 506 was withdrawn at 
100 days. the 3 survivinlt animals remained clinically well for 2 
months. at which time liver biopsies showed cellular infiltrates. 
One animal died after biopsy. but the other 2 lived for an 
additional 84 and 109 days without therapy before their xeno· 
grafts were slowly rejected. The 7 heart recipients who survived 
for 100 days are alive with beating hearts after a further 15-20 
FIGURE 1. Hamster liver (Ai and heart IB) 
in native state and 100 days after transplan· 
,.. tation to rats Ie and Dl. Immunoperoxidase 
stain with.L·21·6 mAb and hematoxylin 
counterstam. Orilrinal malmificatlons: top. 
x300: bottom. X120. 
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Jays offtherapy. 
Liver xenografts were sampled during treatment at 3 {n-3), 
30 (n=3). and 60 (n::3) days and beyond the lOO-day treatment 
period (n=3). whereas cardiac xenografts were examined only 
on post-transplant day 100 (n=3). Tissues were studied with a 
previously described standard 3-step avidin-biotin complex 
(ABC) immunoperoxidase technique using the L-21-6 mouse 
mAb that recognizes class II antigens in Lewis rats (2, 3) and 
a variety for other inbred rat strains. No staining for L·21-6 
was detected in normal hamster liver. heart. or spleen (3 
samples each). 
In contrast. by day 3 after liver transplantation. occasional 
spindled and round sinusoidal and ponal cells were L-21-6 
positive in all samples. After transplantation. bile ducts. hepa-
tocytes. and vascular endothelial cells remained L-21-6 negative 
(donor type) throughout (Fig. lAI. From day 30 onward. 
whether the grafts were histologically normal or contained a 
mononuclear portal infiltrate. most of the portal inflammatory 
cells. Sinusoidal Kupffer cells. dendritic-shaped cells in the 
triads. and spindle cells beneath hepatic venules and in the 
capsule were L·21-6" and thus of recipient origin. Although 
most of the infiltrative cell populations were L-21-6+. 3 distinct 
cell sub!n'oups could be distin/nlished based on location. im-
munophenotype. and morphology. L-21-6+ /ED2+ cells with 
abundant cytoplasm located in the sinusoids and at the edge of 
the triads were most likely of macrophage lineage. L-21-6+ I 
OX33" small round cells in the triads. arranged in nodules. 
were probably B cells. Finally, L-21-6+ /ED2- dendritic shaped 
cells present in the center of the triads. often near bile ducts, 
are most likely dendritic cells. 
By day 100. the number of L-21-6+ cells in the portal tracts 
had reached their maximum. Cardiac xenografts sampled on 
day 100 also had intensely L-21-6+ (recipient origin) spindle-
shaped dendritic reticulum cells scattered throughout the in-
terstitium and around arteries (Fig. 1B). These observations 
were constant in all liver and heart samples with minimum 
variability. 
Cell replacement in the liver allografts was originally ob-
served by K. A. Poner in human liver allografts many years 
ago (4. 5) and was noted recently by Yamaguchi et a1. (6) in a 
hamster to rat hepatic xenograft that had survived for 83 days. 
The findings in the liver and hean xenografts reported here 
support the contention that dendritic cell repopulation is ge-
neric to the acceptance of all grafts (7). It is noteworthy that 
repopulated hepatic and cardiac xeDografta had prolonpci sur-
vival after stopping treatment before they were slowly rejected. 
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HUMAN CDS+ XENOREACTIVE T CELLS MEDIATE TISSUE INJURY IN VIVO 
There has been longstanding interest in the possibility of 
transplanting organs or tissues from other species into man 
( 1). Studies of human xenogeneic T cell immune responses 
have demonstrated that the generation of the cytotoxic re-
sponse involves. as in allogeneic responses. primarily CD4 
helper and CDS cytotoxic T cells (2-4). The specificity of 
xenogeneic antigen recognition by human cytotoxic T cells for 
polymorphic determinants of antigens encoded by the MHC of 
another species is comparable to that of alloantigen recognition 
(2. 3. 5), and can be assessed perhaps most easily in human 
antimouse responses due to the ready availability of murine 
target cells with defmed antigen expression. The human T cell 
subsets responsible for mediating xenogeneic or allogeneic tis-
sue destruction in vivo remain unclear. with evidence for con-
tributions by both CD4+ and CDS+ T cells and NK cells in the 
latter (6, 7). In these studies. we have investigated human T 
cell effector function in vivo, using characterized human anti-
mouse effector cell populations adoptively transferred into mu-
rine hosts. 
Human antimurine effector cells of defined antigen specific-
ity were obtained from a secondary mixed lymphocyte culture 
with C57BL/6 cells as stimulators and human peripheral bJood 
cells as responders. Human antihuman alloreactive lines were 
similarly obtained with repeated stimulation of human re-
sponder cells from the same donor by an EBV -transformed B 
cell line carrying both class 1 and class I disparities as compared 
to the responder. The alloreactive line 302 and the xenoreactive 
lines 124 and 159 were obtained by limiting the dilution of a 
